HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients

Journal of Clinical Endocrinology and Metabolism

Volumn 85, Issue 3, 2000, Pages 1137-1142

  Chung, Yoon Sok ^a   Lee, Mi Deok ^a   Lee, Seong Kyu ^a   Kim, Hyeon Man ^a   Fitzpatrick, Lorraine A ^b  

^a Ajou University School of Medicine   (South Korea)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

ADULT; AGE; AGED; ARTICLE; BODY MASS; BONE DENSITY; CONTROLLED STUDY; DRUG EFFECT; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR NECK; GLUCOSE BLOOD LEVEL; HIP; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEX DIFFERENCE; SPINE;

BONE DENSITY; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; OSTEOPOROSIS; RETROSPECTIVE STUDIES;

EID: 0034454445     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.85.3.1137     Document Type: Article

References (23)

1. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo
2. Bisphosphonates act on rat bone-resorption through the mediation of osteoblasts
3. Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: Evidence from structure-activity relationships in J774 macrophages
4. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras
5. Alendronate mechanism of action: Geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro
6. Stimulation of bone formation in vitro and in rodents by stafins
7. Chronic I.V. aminobisphosphonate therapy increases HDL cholesterol. Proceedings of the Second Joint Meeting of The American Society for Bone and Mineral Research, San Francisco, CA
8. Nitrogen-containing bisphosphonares act directly on the osteoclast: Induction of Mst 1 kinase clevage, minicked by lovastatin, is blocked by geranylgeraniol and caspase inhibitors
9. Alendronate mechanism of action: Inhibtion of osteoclastogenesis and bone resorption are mimicked by lovastatin and blocked by geranylgeraniol
10. Statin use, bone mass and fracture: An analysis of two prospective studies. Proceedings of the 21st Annual Meeting of The American Society for Bone and Mineral Research, St. Louis, MO
11. Use of hormone replacement therapy by postmenopausal women in the United States
12. Bone mineral metabolism in human type 1(insulin dependent) diabetes mellitus
13. Diabetic osteopenia and circulating levels of vit D metabolites in type 2(noninsulin-dependent) diabetes
14. Bone mineral density in women with type II diabetes mellitus
15. Bone mass and sex steroid concentrations in postmenopausal Caucasian diabetics
16. The relationship of diabetes mellitus and body weight to osteoporosis in elderly female
17. Effects of dietary carbohydrates on metabolism of calcium and other minerals in normal subjects and patient with noninsulin-dependent diabetes mellitus
18. Suggestion of a deficient osteoblastic function in diabetes mellitus: The possible cause of osteopenia in diabetics
19. Effect of hormones and growth factors on alkaline phosphatase activity and collagen synthesis in cultured rat calvariae
20. Growth-inhibitory effect of a high glucose concentration on osteoblast-like cells
21. The role of geranylgeranylation in bone resorption and it suppression by bisphophonates in fetal bone explants in vitro: A clue to the mechanism of action of nitrogencontaining bisphophonates
22. Distribution of Prenyltransferases in rat tissue
23. The microanatomy of trabecular bone loss in normal aging men and women